标题
Cardiovascular effects of the DPP-4 inhibitors
作者
关键词
-
出版物
Diabetes & Vascular Disease Research
Volume 9, Issue 2, Pages 109-116
出版商
SAGE Publications
发表日期
2012-02-16
DOI
10.1177/1479164111436236
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
- (2011) J. Shirakawa et al. DIABETES
- DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
- (2011) D. Dicker DIABETES CARE
- Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes
- (2011) Susumu Ogawa et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
- (2011) Zubair Shah et al. VASCULAR PHARMACOLOGY
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice
- (2010) A. D. Dobrian et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes
- (2010) Nga N. Ta et al. ATHEROSCLEROSIS
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2011
- (2010) DIABETES CARE
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Adipocyte Turnover: Relevance to Human Adipose Tissue Morphology
- (2009) E. Arner et al. DIABETES
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
- (2008) Michael Boschmann et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now